Wandercraft's Atalante X exoskeleton receives expanded CE certification, with indications adding tetraplegia and other neurological conditions

Wandercraft announced that its self-balancing Atalante X exoskeleton has received expanded CE certification, with indications extended to a broader range of neurological conditions including paraplegia, tetraplegia, hemiplegia and their paresis types, and it is already in use at more than 100 rehabilitation centers. The new version supports independent adjustment of assistance force at the hip and knee joints, allows step length to be finely adjusted in 5% increments, and improves reporting data, training processes and safety processes; the new version will ship to European customers starting in October 2025, and FDA clearance is expected by the end of the year.